GlassScriptPhysician profile
Shashank Shekhar
NPI 1356781629
$776.96
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $123 · 2021: $271 · 2022: $151 · 2023: $22.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $136.98 | 2021 | |
| Ucb, INC. | $128.88 | 2019-2021 | |
| Boston Scientific Corporation | $96.34 | 2022 | |
| Irras USA, INC. | $88.25 | 2020 | |
| Genzyme Corporation | $80.97 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $42.02 | 2021-2023 | Ultomiris |
| Emd Serono, INC. | $40.69 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $40.41 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $20.73 | 2021 | |
| Greenwich Biosciences, INC. | $19.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.46 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.01 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.42 | 2022 | |
| Acorda Therapeutics, INC | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashank Shekhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.